Pre-market hot trades in US stocks: Micron Tech up 3.86% in pre-market; Abbvie down 3.85% in pre-market
Complete. Here is the key summaryMicron Tech pre-market rose 3.86%; Abbvie pre-market fell 3.85%; Microbus pre-market rose 317.33%; Focus Media pre-market rose 150.00%; Mangoceuticals pre-market rose 132.49%
Pre-market Hot Trades in US Stocks
Micron Technology rose 3.86% in pre-market trading. Based on recent key news:
-
On July 31, Moody's upgraded Micron Technology's senior unsecured rating to Baa1 with a stable outlook. This rating upgrade reflects market confidence in Micron's financial condition, driving the stock price up.
-
On July 30, Samsung Electronics reported record operating profits and sales, expecting the chip shortage to worsen and persist until 2028. This news boosted market expectations for memory chip stocks like Micron, leading to a significant rebound in stock prices.
-
On July 28, Changxin Technology was listed on the Shanghai Stock Exchange's STAR Market, triggering a global sell-off in the memory chip sector, which caused Micron's stock price to drop by 2.25%. Changxin's listing changed the competitive landscape of the DRAM market, increasing market uncertainty. Demand for memory chips remains strong, and market volatility has intensified.
AbbVie fell 3.85% in pre-market trading. Based on recent key news:
-
On July 31, AbbVie lowered its 2026 earnings forecast to $13.87 to $14.07 per share, down from the previous forecast of $13.91 to $14.11, leading to a 4.4% drop in pre-market stock price.
-
On July 31, AbbVie reported adjusted earnings per share of $3.65 for the second quarter, exceeding analysts' expectations of $3.60, but the lowered full-year earnings forecast raised market concerns, causing a nearly 3% drop in pre-market stock price.
-
On July 31, AbbVie announced the acquisition of Apogee Therapeutics for $10.9 billion, expecting this acquisition to have a dilution impact of $0.14 on 2026 earnings per share, resulting in a pre-market stock price drop of over 4%. The biopharmaceutical industry has performed strongly recently but faces the risk of a patent cliff.
Top Gainers in Pre-market US Stocks
Microbus rose 317.33% in pre-market trading. Based on recent key news:
-
On July 30, Wetour Robotics announced a common stock consolidation plan with a consolidation ratio of 1 to 100, expected to take effect on August 3. This move aims to increase the stock price and improve market liquidity, leading to a significant rise in stock price.
-
On July 29, the SEC issued a notice reminding investors not to overly rely on forward-looking statements and emphasized that the company discussed additional factors in its SEC filings. This announcement increased market confidence in the company's future development, driving the stock price up.
-
On July 29, Fermi and Galaxy Digital faced challenges in responding to changes in cryptocurrency regulation, causing fluctuations in investor interest in risk assets. Traditional commodity tools provided mixed signals, further exacerbating market uncertainty. In this context, Microbus has attracted attention as a safe-haven asset, leading to a rise in stock price. The market reacted strongly to changes in cryptocurrency regulation, increasing demand for safe-haven assets.
Fengzhong Global rose 150% in pre-market trading. Fengzhong Global has had no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation no_news
Mangoceuticals pre-market rose 132.49%. Based on recent key news:
-
On July 30, Mangoceuticals announced a new product announcement, stating that its latest developed drug has received FDA approval. This news greatly boosted market confidence, leading to a significant increase in stock prices.
-
On July 29, the company released its second-quarter financial report, showing that its revenue and net profit exceeded market expectations. The financial report data indicated strong business performance, further driving up the stock price.
-
On July 28, analysts upgraded Mangoceuticals' rating, believing that its future growth potential is enormous. The analysts' positive evaluations attracted more investor attention, promoting the rise in stock prices. The pharmaceutical industry has performed strongly recently, with significant capital inflows
